Finance

Lists
Q3 2026 earnings • released • EPS miss -4.21% • Revenue miss -19.44%
See results
LENZ:NASDAQ
Lenz Therapeutics Inc
$3.05
0.00%
(0.00) 1D
$3.10
+1.64% (+0.050)
Pre-market
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LENZ...
Open
$3.07
High
$3.19
Low
$2.80
Mkt. cap
95.83M
Avg. vol.
958.32K
Volume
100.00
52-wk high
$32.13
52-wk low
$2.80
EPS
-$4.08
Beta
0.65
Shares outstanding
31.42M
No. of employees
152
Open
$3.07
High
$3.19
Low
$2.80
Mkt. cap
95.83M
Avg. vol.
958.32K
Volume
100.00
52-wk high
$32.13
52-wk low
$2.80
EPS
-$4.08
Beta
0.65
Shares outstanding
31.42M
No. of employees
152
News stories
From web sources and news partners
About Lenz Therapeutics Inc
CEO-
Employees152
Founded2013
HeadquartersSolana Beach, California, United States
SectorPharmaceutical industry
Websitelenz-tx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LENZ in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LENZ in the last 3 months.
Highest
Current $3.05
$45.00 (+1,375.41%)
Average
$16.00 (+424.59%)
Lowest
$4.00 (+31.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Hold
Reiterated
$4.00
+31.1%
10/30/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$16.00
+424.6%
10/30/2026
Stacy Ku
TD Cowen
Buy
Maintained
$45.00
+1,375.4%
10/29/2026
Biren Amin
Piper Sandler
Hold
Maintained
$5.00
+63.9%
10/19/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$10.00
+227.9%
08/13/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
-$0.99 / -$0.95
-4.21%miss
Revenue / Est. (USD)
3.38M / 4.20M
-19.44%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.59M
1.90M
5.49M
3.38M
Cost of goods sold
418.00K
1.08M
280.00K
454.00K
Cost of revenue
418.00K
1.08M
280.00K
454.00K
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.63M
44.96M
39.38M
35.85M
Operating expense
39.63M
44.96M
39.38M
35.85M
Total operating expenses
40.05M
46.04M
39.66M
36.30M
Operating income
-38.46M
-44.14M
-34.17M
-32.92M
Other non operating income
-417.00K
3.00K
-13.00K
-36.00K
EBT including unusual items
-35.89M
-41.49M
-31.92M
-30.97M
EBT excluding unusual items
-35.89M
-41.49M
-31.92M
-30.97M
Income tax expense
2.00K
-
3.00K
-
Effective tax rate
-0.01%
-
-0.01%
-
Other operating expenses
-
-
-
-
Net income
-35.90M
-41.49M
-31.92M
-30.97M
Net profit margin
-2,260.45%
-2,182.43%
-581.81%
-915.16%
Earnings per share
-1.16
-1.32
-1.02
-0.99
Interest and investment income
2.99M
2.64M
2.27M
1.98M
Interest expense
-
-
-
-
Net interest expenses
2.99M
2.64M
2.27M
1.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.36M
-44.02M
-34.06M
-32.81M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps